Irvine, CA, April 4, 2018 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing…
Read More
News
Home »
Thomas P. Loughran, Jr., MD, is the director of the UVA Cancer Center, F. Palmer…
Irvine, CA, December 6, 2017 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company leading…
— First Data from BNZ-1 Phase 1 trial to be Highlighted in Oral Presentation- Irvine,…
— Company’s product candidate BNZ-2, potentially constitutes a unique therapeutic approach for patients with Celiac…
— Favorable Safety, Pharmacokinetics and Robust Pharmacodynamic Activity Demonstrated in Healthy Volunteers- Irvine, CA, July…
IRVINE, Calif., Dec. 20, 2016 /PRNewswire/ — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company…
-IND Accepted by the FDA for Lead Development Program addressing HTLV-1 Associated Myelopathy (HAM) and…
Thomas A. Waldmann, M.D. received his M.D. from Harvard Medical School. He joined the NCI…
Dr. Yutaka Tagaya is the scientific co-founder of the company and a leading expert in…
